MG
MDGL icon

Mather Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mather Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39K Hold
73
– – ﹤0.01% 1166
2026
Q1 		$38.1K Buy
+73
New +$34.9K ﹤0.01% 1119
2025
Q4 		– Sell
-73
Closed -$33.3K – 1250
2025
Q3 		$33.3K Buy
+73
New +$27.2K ﹤0.01% 999
2025
Q2 		– Sell
-73
Closed -$24.1K – 1278
2025
Q1 		$24.1K Hold
73
– – ﹤0.01% 1050
2024
Q4 		$22.4K Hold
73
– – ﹤0.01% 1056
2024
Q3 		$15.4K Hold
73
– – ﹤0.01% 1109
2024
Q2 		$19.4K Buy
+73
New +$17.4K ﹤0.01% 1267

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mather Group's MDGL Position: Q2 2026 in Review

Mather Group held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 73 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #1166.

Mather Group first reported a position in MDGL in Q2 2024 and has held it in 7 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Mather Group held 73 shares of Madrigal Pharmaceuticals worth $39K as of Q2 2026.
  • Mather Group left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1166 holding.
  • Mather Group first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.